Literature DB >> 8450045

Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.

S van Weely1, M van den Berg, J A Barranger, M C Sa Miranda, J M Tager, J M Aerts.   

Abstract

The properties of control and 370Asn-->Ser glucocerebrosidase, the frequently encountered mutated form of the enzyme in type 1 Gaucher disease, were studied in vitro as well as in situ. The catalytic properties of purified 370Asn-->Ser glucocerebrosidase were highly dependent on the assay conditions. The enzyme was deficient in activity towards substrate and in reactivity with the irreversible inhibitor conduritol B-epoxide (CBE) when activated by the bile salt taurocholate. In the presence of more physiological activators, the lysosomal activator protein saposin C and phosphatidylserine, the 370Asn-->Ser enzyme was near normal in kinetic properties at pH values approximately 5, but not at higher pH. In intact fibroblasts, the enzymic activity of the 370Asn-->Ser glucocerebrosidase and its reactivity with CBE were found to be clearly deficient. However, in intact lymphoblasts from the same patients, the behavior of the mutant enzyme was near normal. The catalytic efficiency of 370Asn-->Ser glucocerebrosidase in situ was also found to be highly pH dependent. When intact lymphoblasts were cultured in the presence of permeant weak bases, which increase the pH of acidic intracellular compartments, the catalytic efficiency of the mutant enzyme, as assessed by its reactivity with CBE, became markedly impaired. Our findings indicate that the intralysosomal pH in the intact cell can be expected to have a critical influence on the activation state of 370Asn-->Ser glucocerebrosidase and its ability to hydrolyse substrate. This phenomenon may partly underly the marked heterogeneity in clinical manifestation of Gaucher disease among patients with this mutated form of glucocerebrosidase.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8450045      PMCID: PMC288073          DOI: 10.1172/JCI116276

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

Review 1.  Saposin proteins: structure, function, and role in human lysosomal storage disorders.

Authors:  J S O'Brien; Y Kishimoto
Journal:  FASEB J       Date:  1991-03-01       Impact factor: 5.191

2.  High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.

Authors:  A Zimran; T Gelbart; B Westwood; G A Grabowski; E Beutler
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

Review 4.  Gaucher disease: new molecular approaches to diagnosis and treatment.

Authors:  E Beutler
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

5.  Human acid beta-glucosidase. Use of conduritol B epoxide derivatives to investigate the catalytically active normal and Gaucher disease enzymes.

Authors:  G A Grabowski; K Osiecki-Newman; T Dinur; D Fabbro; G Legler; S Gatt; R J Desnick
Journal:  J Biol Chem       Date:  1986-06-25       Impact factor: 5.157

6.  A case of nonneurologic Gaucher's disease that biochemically resembles the neurologic types.

Authors:  R H Glew; V Gopalan; C A Hubbell; E Beutler; J D Geil; R E Lee
Journal:  J Neuropathol Exp Neurol       Date:  1991-03       Impact factor: 3.685

7.  Mutations in Jewish patients with Gaucher disease.

Authors:  E Beutler; T Gelbart; W Kuhl; A Zimran; C West
Journal:  Blood       Date:  1992-04-01       Impact factor: 22.113

8.  Gaucher disease: heterologous expression of two alleles associated with neuronopathic phenotypes.

Authors:  M E Grace; A Berg; G S He; L Goldberg; M Horowitz; G A Grabowski
Journal:  Am J Hum Genet       Date:  1991-09       Impact factor: 11.025

9.  DNA mutation analysis of Gaucher patients.

Authors:  E Sidransky; S Tsuji; B M Martin; B Stubblefield; E I Ginns
Journal:  Am J Med Genet       Date:  1992-02-01

10.  Identification of the second common Jewish Gaucher disease mutation makes possible population-based screening for the heterozygous state.

Authors:  E Beutler; T Gelbart; W Kuhl; J Sorge; C West
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

View more
  19 in total

1.  Ultrasensitive in situ visualization of active glucocerebrosidase molecules.

Authors:  Martin D Witte; Wouter W Kallemeijn; Jan Aten; Kah-Yee Li; Anneke Strijland; Wilma E Donker-Koopman; Adrianus M C H van den Nieuwendijk; Boris Bleijlevens; Gertjan Kramer; Bogdan I Florea; Berend Hooibrink; Carla E M Hollak; Roelof Ottenhoff; Rolf G Boot; Gijsbert A van der Marel; Herman S Overkleeft; Johannes M F G Aerts
Journal:  Nat Chem Biol       Date:  2010-10-31       Impact factor: 15.040

2.  Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.

Authors:  Samarjit Patnaik; Wei Zheng; Jae H Choi; Omid Motabar; Noel Southall; Wendy Westbroek; Wendy A Lea; Arash Velayati; Ehud Goldin; Ellen Sidransky; William Leister; Juan J Marugan
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

3.  Gaucher disease: variability in phenotype among siblings.

Authors:  D Amato; T Stachiw; J T R Clarke; G E Rivard
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

4.  Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation.

Authors:  Clarence K Zhang; Philip B Stein; Jun Liu; Zuoheng Wang; Ruhua Yang; Judy H Cho; Peter K Gregersen; Johannes M F G Aerts; Hongyu Zhao; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

Review 5.  Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease.

Authors:  J M Aerts; S Van Weely; R Boot; C E Hollak; J M Tager
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

6.  Effects of calcium on phosphatidylserine- and saposin C-stimulated glucosylceramide beta-glucosidase activity.

Authors:  E M Prence
Journal:  Biochem J       Date:  1995-09-01       Impact factor: 3.857

7.  Substrate reduction therapy of glycosphingolipid storage disorders.

Authors:  Johannes M F G Aerts; Carla E M Hollak; Rolf G Boot; Johanna E M Groener; Mario Maas
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

8.  The N370S (Asn370-->Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C.

Authors:  Rosa Salvioli; Massimo Tatti; Susanna Scarpa; Sabrina Maria Moavero; Fiorella Ciaffoni; Federica Felicetti; Christine R Kaneski; Roscoe O Brady; Anna Maria Vaccaro
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

9.  Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses.

Authors:  Fredj Ben Bdira; Marta Artola; Herman S Overkleeft; Marcellus Ubbink; Johannes M F G Aerts
Journal:  J Lipid Res       Date:  2018-10-02       Impact factor: 5.922

Review 10.  Calcium signaling via two-pore channels: local or global, that is the question.

Authors:  Michael X Zhu; Jianjie Ma; John Parrington; Peter J Calcraft; Antony Galione; A Mark Evans
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-16       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.